Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.
BACKGROUND
Previous clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization strategy involving priming with canarypox vCP1521 followed by boosting with rgp120 could provide significant, although modest, protection from HIV infection. Based on these results, there is renewed interest in the development of rgp120 based antigens for follow up vaccine trials, where this immunization approach can be applied to other cohorts at high risk for HIV infection. Of particular interest are cohorts in Africa, India, and China that are infected with clade C viruses.


RESULTS
A panel of 10 clade C rgp120 envelope proteins was expressed in 293 cells, purified by immunoaffinity chromatography, and used to immunize guinea pigs. The resulting sera were collected and analyzed in checkerboard experiments for rgp120 binding, V3 peptide binding, and CD4 blocking activity. Virus neutralization studies were carried out with two different assays and two different panels of clade C viruses. A high degree of cross reactivity against clade C and clade B viruses and viral proteins was observed. Most, but not all of the immunogens tested elicited antibodies that neutralized tier 1 clade B viruses, and some sera neutralized multiple clade C viruses. Immunization with rgp120 from the CN97001 strain of HIV appeared to elicit higher cross neutralizing antibody titers than the other antigens tested.


CONCLUSIONS
While all of the clade C antigens tested were immunogenic, some were more effective than others in eliciting virus neutralizing antibodies. Neutralization titers did not correlate with rgp120 binding, V3 peptide binding, or CD4 blocking activity. CN97001 rgp120 elicited the highest level of neutralizing antibodies, and should be considered for further HIV vaccine development studies.
Smith
Douglas H
DH
VaxGen, Inc., Brisbane, California, United States of America.
Winters-Digiacinto
Peggy
P
Mitiku
Misrach
M
O'Rourke
Sara
S
Sinangil
Faruk
F
Wrin
Terri
T
Montefiori
David C
DC
Berman
Phillip W
PW
D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D002460:Cell Line; D006168:Guinea Pigs; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000145:classification* / Q000276:immunology*; D007106:Immune Sera / Q000276:immunology; D007117:Immunization, Secondary; D009500:Neutralization Tests
D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D007106:Immune Sera